JPH10500300A - 単球走化性蛋白質−4 - Google Patents
単球走化性蛋白質−4Info
- Publication number
- JPH10500300A JPH10500300A JP7529592A JP52959295A JPH10500300A JP H10500300 A JPH10500300 A JP H10500300A JP 7529592 A JP7529592 A JP 7529592A JP 52959295 A JP52959295 A JP 52959295A JP H10500300 A JPH10500300 A JP H10500300A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- mcp
- polynucleotide
- sequence
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)図1の推定アミノ酸配列を有するMCP−4ポリペプチドまたは該 ポリペプチドのフラグメント、アナログもしくは誘導体をコードするポリヌクレ オチド、 (b)ATCC受託番号75703に含まれるcDNAによってコードされる アミノ酸配列を有するポリペプチドまたは該ポリペプチドのフラグメント、アナ ログもしくは誘導体をコードするポリヌクレオチド からなる群から選ばれる単離されたポリヌクレオチド。 2.ポリヌクレオチドがDNAである請求項1記載のポリヌクレオチド。 3.ポリヌクレオチドがRNAである請求項1記載のポリヌクレオチド。 4.ポリヌクレオチドがゲノムDNAである請求項1記載のポリヌクレオチド 。 5.ポリヌクレオチドが図1の推定アミノ酸配列を有するMCP−4をコード する請求項2記載のポリヌクレオチド。 6.ポリヌクレオチドが、ATCC受託番号75703のcDNAによってコ ードされるMCP−4ポリペプチドをコードする請求項2記載のポリヌクレオチ ド。 7.図1で示されるMCP−4のコーディング配列を有する請求項1記載のポ リヌクレオチド。 8.ATCC受託番号75703として寄託されたMCP−4のコーディング 配列を有する請求項2記載のポリヌクレオチド。 9.請求項2記載のDNAを含むベクター。 10.請求項9記載のベクターで遺伝子操作された宿主細胞。 11.請求項10記載の宿主細胞から該DNAによりコードされるポリペプチ ドを発現させることからなるポリペプチドの製法。 12.請求項9記載のベクターで遺伝子操作された細胞からなる、ポリペプチ ドを発現する能力を有する細胞の製法。 13.請求項2記載のDNAとハイブリダイズし、かつMCP−4活性を有す るポリペプチドをコードする単離DNA。 14.(i)図1の推定アミノ酸配列を有するMCP−4ポリペプチド、その フラグメント、アナロおよび誘導体ならびに(ii)ATCC受託番号7570 3のcDNAによってコードされるMCP−4ポリペプチド、そのフラグメント 、アナログおよび誘導体からなる群から選ばれるポリペプチド。 15.ポリペプチドが、図1の推定アミノ酸配列を有するMCP−4である請 求項14記載のポリペプチド。 16.請求項14記載のポリペプチドに対する抗体。 17.請求項14記載のポリペプチドに対するアゴニスト。 18.請求項14記載のポリペプチドに対する拮抗剤/抑制剤。 19.MCP−4の必要な患者に対して治療有効量の請求項14記載のポリペ プチドを投与することを特徴とする該患者の治療方法。 20.MCP−4の抑制の必要な患者に治療有効量の請求項18記載の拮抗剤 /抑制剤を投与することを特徴とする該患者の治療方法。 21.請求項14記載のポリペプチドと、医薬上許容される担体とからなる医 薬組成物。 22.患者に該ポリペプチドをコードするDNAを与え、in vivoで該ポリペ プチドを発現させることにより、治療有効量のポリペプチドを投与する請求項1 9記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1994/005384 WO1995031467A1 (en) | 1994-05-16 | 1994-05-16 | Monocyte chemotactic protein-4 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10500300A true JPH10500300A (ja) | 1998-01-13 |
JP3670665B2 JP3670665B2 (ja) | 2005-07-13 |
Family
ID=22242565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52959295A Expired - Fee Related JP3670665B2 (ja) | 1994-05-16 | 1994-05-16 | 単球走化性蛋白質−4 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0767796B1 (ja) |
JP (1) | JP3670665B2 (ja) |
KR (1) | KR970703353A (ja) |
AT (1) | ATE206162T1 (ja) |
AU (1) | AU695174B2 (ja) |
DE (1) | DE69428460T2 (ja) |
NZ (1) | NZ266979A (ja) |
PT (1) | PT767796E (ja) |
WO (1) | WO1995031467A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT719331E (pt) | 1993-09-14 | 2007-01-31 | Imp Innovations Ltd | Eotaxina-citocina quimiotáctica de eosinófilos |
US5866373A (en) * | 1995-04-21 | 1999-02-02 | Human Genome Sciences, Inc. | Polynucleotide encoding a human chemotactic protein |
US6075124A (en) * | 1994-05-16 | 2000-06-13 | Human Genome Sciences, Inc. | Human chemotactin protein |
US6100389A (en) | 1995-04-21 | 2000-08-08 | Human Genome Sciences, Inc. | Polynucleotides encoding a human chemotactic protein |
US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
US6391589B1 (en) | 1994-08-23 | 2002-05-21 | Human Genome Sciences, Inc. | Human chemokine beta-10 mutant polypeptides |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
US6537764B1 (en) * | 1995-01-19 | 2003-03-25 | Children's Medical Center Corporation | Method of identifying inhibitors of C—C chemokine receptor 3 |
CA2237998A1 (en) * | 1995-11-15 | 1997-05-22 | Incyte Pharmaceuticals, Inc. | Chemokine from niddm pancreas |
EP0885293B1 (en) * | 1996-02-23 | 2006-06-07 | Human Genome Sciences, Inc. | Human chemokine polypeptides |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
US6028169A (en) * | 1997-03-31 | 2000-02-22 | Human Genome Sciences, Inc. | Chemokine β-6 antagonists |
ATE232399T1 (de) * | 1997-04-04 | 2003-02-15 | Max Planck Gesellschaft | Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen |
DE10162869A1 (de) * | 2001-12-20 | 2003-07-31 | Alexander Cherkasky | Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger |
WO2003092597A2 (en) | 2002-05-01 | 2003-11-13 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
PE20180249A1 (es) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2669930A1 (fr) * | 1990-11-29 | 1992-06-05 | Sanofi Sa | Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention. |
-
1994
- 1994-05-16 KR KR1019960706480A patent/KR970703353A/ko not_active Application Discontinuation
- 1994-05-16 WO PCT/US1994/005384 patent/WO1995031467A1/en active IP Right Grant
- 1994-05-16 NZ NZ266979A patent/NZ266979A/xx not_active IP Right Cessation
- 1994-05-16 PT PT94917388T patent/PT767796E/pt unknown
- 1994-05-16 DE DE69428460T patent/DE69428460T2/de not_active Expired - Fee Related
- 1994-05-16 AT AT94917388T patent/ATE206162T1/de not_active IP Right Cessation
- 1994-05-16 AU AU69130/94A patent/AU695174B2/en not_active Ceased
- 1994-05-16 EP EP94917388A patent/EP0767796B1/en not_active Expired - Lifetime
- 1994-05-16 JP JP52959295A patent/JP3670665B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0767796A1 (en) | 1997-04-16 |
DE69428460D1 (de) | 2001-10-31 |
PT767796E (pt) | 2002-03-28 |
AU6913094A (en) | 1995-12-05 |
JP3670665B2 (ja) | 2005-07-13 |
ATE206162T1 (de) | 2001-10-15 |
AU695174B2 (en) | 1998-08-06 |
KR970703353A (ko) | 1997-07-03 |
DE69428460T2 (de) | 2002-05-23 |
EP0767796A4 (en) | 1997-06-11 |
NZ266979A (en) | 1999-01-28 |
WO1995031467A1 (en) | 1995-11-23 |
EP0767796B1 (en) | 2001-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5504003A (en) | Macrophage inflammatory protein-3 and -4 | |
EP0735818B1 (en) | MACROPHAGE INFLAMMATORY PROTEINS MIP-3, MIP-4 AND MIP-1gamma | |
EP0792278B1 (en) | Tumor necrosis factor-gamma | |
AU708903B2 (en) | Human chemokine polypeptides | |
US5922572A (en) | Polynucleotides encoding haemopoietic maturation factor | |
US7198944B2 (en) | Human chemokine β-9 viral vectors | |
AU723891B2 (en) | Human chemokine beta-11 and human chemokine alpha-1 | |
US5556767A (en) | Polynucleotide encoding macrophage inflammatory protein γ | |
JPH10500300A (ja) | 単球走化性蛋白質−4 | |
JP3774230B2 (ja) | ケラチノサイト増殖因子−2 | |
CA2211003A1 (en) | Human tumor necrosis factor receptor | |
US5958400A (en) | Interleukin-6 splice variant | |
JPH10513355A (ja) | ヒトケモカインβ−11およびヒトケモカインα−1 | |
JPH10500301A (ja) | マクロファージ遊走阻止因子−3 | |
JPH11507237A (ja) | 単球走化性蛋白質−4 | |
EP0777494B1 (en) | Human chemokine polypeptides | |
EP1006188B1 (en) | Human chemokine polypeptides | |
AU753088B2 (en) | Human chemokine polypeptides | |
AU767527B2 (en) | Human chemokine polypeptides | |
EP1125948A1 (en) | Monocyte chemotactic protein-4 | |
US5945321A (en) | Ubiquitin conjugating enzymes 7, 8 and 9 | |
CA2190466A1 (en) | Monocyte chemotactic protein-4 | |
KR19990087164A (ko) | 사람 케모킨 폴리펩티드 | |
JP2002320492A (ja) | ヒトケモカインβ−11およびヒトケモカインα−1 | |
JPH11503007A (ja) | ヒト腫瘍壊死因子受容体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050415 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090422 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |